TAK-875 is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 0.072 μM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | GPR40 is one of the G protein-coupled receptors predominantly expressed in pancreatic β-cells, which mediates enhancement of glucose-stimulated insulin secretion by free fatty acids. TAK-875 is a potent, selective, and orally bioavailable anago-allosteric modulator of hGPR40 with EC50 value of 14nM in a FLIPR assay. TAK-875 can stimulate glucose-dependent insulin secretion, making it act in a unique mode for the treatment of type-2 diabetes mellitus. Single oral dosing of TAK-875 at dose of 3mg/kg, at 1h prior to the oral glucose challenge, reduced the blood glucose excursion and augmented insulin secretion in female Wistar fatty rats. Six-week treatment with combination of TAK-875 (10 mg/kg, b.i.d.) with metformin (50 mg·kg−1, q.d.) significantly potentiate their effect alone on decrease of glycosylated Hb and increase in fasting plasma insulin levels, as well as maintained pancreatic insulin content to the same level compared with normal rats without affecting pancreatic glucagon content in Zucker diabetic fatty rats. |
作用机制 | TAK-875 can interact with GPR40 directly through three groups of interactions and form a complex is in an inactive-like state.[1][2] |
Dose | Rat: 3 mg/kg - 30 mg/kg[4] (p.o.), 1000 mg/kg[5] (p.o.) |
Administration | p.o. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01433393 | Diabetes Mellitus | Phase 3 | Completed | - | Japan ... 展开 >> Kisarazu-shi, Chiba, Japan Matsuyama-shi, Ehime, Japan Fukuoka-shi Nishi-ku, Fukuoka, Japan Kasuga-shi, Fukuoka, Japan Naka-shi, Ibaragi, Japan Tsuchiura-shi, Ibaragi, Japan Takamatsu-shi, Kagawa, Japan Kyoto-shi Fushimi-ku, Kyoto, Japan Nagasaki-shi, Nagasaki, Japan Kashihara-shi, Nara, Japan Kashiwara-shi, Osaka, Japan Osaka-shi Tsurumi-ku, Osaka, Japan Sakai-shi Nishi-ku, Osaka, Japan Shimotsuke-shi, Tochigi, Japan Chiyoda-ku, Tokyo, Japan Itabashi-ku, Tokyo, Japan Ota-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan 收起 << |
NCT01585792 | Diabetic Patients | Phase 3 | Completed | - | Japan ... 展开 >> Fukuoka-shi, Fukuoka, Japan Sumida-ku, Tokyo, Japan 收起 << |
NCT01007097 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | - |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.91mL 0.38mL 0.19mL |
9.53mL 1.91mL 0.95mL |
19.06mL 3.81mL 1.91mL |
CAS号 | 1000413-72-8 |
分子式 | C29H32O7S |
分子量 | 524.63 |
SMILES Code | O=C(O)C[C@@H]1COC2=CC(OCC3=CC(C4=C(C)C=C(OCCCS(=O)(C)=O)C=C4C)=CC=C3)=CC=C12 |
MDL No. | MFCD18251445 |
别名 | Tak-875 |
运输 | 蓝冰 |
InChI Key | BZCALJIHZVNMGJ-HSZRJFAPSA-N |
Pubchem ID | 24857286 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, room temperature |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|